looking at the significant rules issued by CMS and the FDA, the associated cost-benefit analyses used a median value of $293,000 and $300,000, respectively, for an incremental year of life.Thus, as life-saving cancer drug paradigms are developed, it would appear that costs of these drug combinations on the order of $200,000–$300,000 per life-year could be justified using health agencies’ own analyses.
Source: U.S. Government Agencies Have Placed A Value On An Extra Year of Life (It’s Higher Than You Think)
The Health Policy Skeptic 